Higher ADK levels track stronger triciribine effects in leukemia cells, pointing to a potential biomarker
In a comprehensive study of acute lymphoblastic leukemia, researchers at Karolinska Institutet have shown that the enzyme ADK plays an important role in determining how leukemia cells respond to triciribine. Published in npj Precision Oncology, the study also provides new insights into how the compound works and identifies ADK as a potential biomarker for predicting its effects on leukemia cells.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
New drug could let some rectal cancer patients skip chemotherapy, radiation and surgery
United Kingdom
-
Rice, fish and pickles: Is the traditional Japanese diet as healthy as we think?
United Kingdom
-
Five at-home strength moves that can make everyday tasks easier
United Kingdom
-
Scientists found a link between Mediterranean diet blood markers and longer survival
United Kingdom
-
Would subsidizing weight-loss drugs make health care fairer?
United Kingdom
-
Fitness tracker data could offer clues about future brain health
United Kingdom
-
A 20-year study of 90,000 adults suggests the type of fish you eat matters
United Kingdom
-
Researchers warn of growing threats to sleep health across Europe
United Kingdom